Kornimate/medical-research-clean huggingface dataset:
treatment of alopecia using follicular stem cells

Conditions: Alopecia

Summary: treatment of alopecia using the injections of cultured stem cells from human hair follicles,(which contain epithelial and mesenchymal cells stem cell)

the aim of the project is to develop a biomedical cell product based on and stem progenitor cells of the hair follicle and dermal papilla, to study its efficacy in the treatment of alopecia.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of alopecia areata, androgenic alopecia and other non-scarring hair loss * the patient can read, understand, follow the examination procedures and complete, if necessary, the required documentation * written informed consent exclusion criteria: * acute or chronic diseases in the stage of decompensation * chronic infectious diseases: hiv, viral hepatitis b, c, tuberculosis * patients who are pregnant, breastfeeding, or fertile patients who are not using adequate contraceptive methods * chronic and protracted mental disorders, all diseases with the presence of the syndrome of dependence on alcohol, drugs and psychoactive substances, any other condition that makes the patient unable to understand the nature, extent and possible consequences of the study or, in the opinion of the researcher, prevents the patient from observing and performing protocol * patients are unable or unwilling to give written informed consent and / or follow research procedures * any other medical condition that, in the opinion of the investigator, may be associated with an increased risk to the patient or may affect the outcome or evaluation of the study
fibrin sealant in renal transplantation

Conditions: Renal Transplantation

Summary: background: post-operative wound complications arise in as many as 50% of kidney transplant recipients. fibrin sealants have been used in many areas of surgery in attempt to reduce the accumulation of post-operative fluid collections with varying success. the use of fibrin products has been proposed as a means of reducing local wound complications in the immunocompromised renal transplant recipient but as yet has not been studied. methods: 145 patients were enrolled and 141 patients were randomized (74 tisseelä fibrin sealant, 67 no tisseelä fibrin sealant) in a prospective manner to receive fibrin sealant or not at the time of their renal transplant. patients were analyzed per the randomization assignment. the operating team was blinded to the decision until after the iliac fossa dissection was complete. the sealant was applied via aerosol to the iliac fossa and renal allograft hilum after completion of the neoureterocystostomy in 5 ml quantity. clinical and radiographic data were reviewed through the usual 8-week follow-up transplant ultrasound. patients in whom the peritoneum was entered were excluded from data analysis. the incidence of lymphocele, wound infection, dehiscence, clinically significant hematoma as defined by necessitating incision and drainage, and urine leak was recorded.


Eligibility criteria:
inclusion criteria: * all renal transplant recipients exclusion criteria: * patients declining study

Keywords: randomised controlled double blinded
investigation into the role of gtn & ripc in cardiac surgery

Conditions: Myocardial Reperfusion Injury

Summary: the purpose of this study is to determine whether glyceryl trinitrate (gtn) reduces injury to the heart during heart-lung bypass surgery in combination with the newer technique of remote ischaemic preconditioning (ripc).

ischaemic heart disease is a leading cause of mortality in the western world. a number of patients undergo coronary artery bypass graft (cabg) surgery as treatment for ischaemic heart disease. with the rise of interventional procedures, patients who are coming to have cabg surgery are higher risk1. remote ischaemic preconditioning (ripc) has been shown to reduce perioperative myocardial injury (pmi) in patients having cabg even when cold blood cardioplegia or intermittent cross clamp fibrillation is used as cardioprotective measures. these patients have a general anaesthetic with multiple infusions including glyceryl trinitrate (gtn). the use of gtn in these patients is based on theoretical assumptions of coronary vasodilation pre operatively along with maintaining graft potency postoperatively. we intend to investigate the effect of gtn in patients undergoing cardiac surgery being subjected to ripc in its role as a nitric oxide (no) donor. exogenous no has been shown to be cardioprotective in animal models.

Eligibility criteria:
inclusion criteria: * age \> 18 years all patients admitted for on- pump cabg and/or valve surgery * able to give consent exclusion criteria: * allergies to excipients of imp and placebo * chronic renal failure (egfr\<30 ml/min/kg) * severe liver disease * peripheral arterial disease * pregnant or lactating women
real time vital sign assessment to predict neurological decline after traumatic brain injury

Conditions: Traumatic Brain Injury

Summary: this study will look to validate predictive algorithms developed in a previous study where we collected relevant data from trauma registry and after using advanced signal-processing and machine-learning, determined prediction scores regarding neuroworsening and other outcomes following traumatic brain injury.


Eligibility criteria:
inclusion criteria: * arrival to the hospital within 6 hours of injury * age \>= 18 years old * patients with traumatic brain injury(tbi). tbi is defined as any alteration or loss of consciousness with or without positive head c.t findings. exclusion criteria: * deemed to have a non-survivable tbi * brain dead on arrival * active substance abuse for opiates and cocaine as noted by admission toxicology screen. * any thoracic or abdominal injury resulting in open surgical intervention * pregnancy * prisoners * active military * non - english speaking (due to necessity for consent in aims 2 and 3) * age \> 89 years
the respond registry

Conditions: Partial Thickness Wound; Pressure Ulcer; Venous Ulcer; Diabetic Ulcer; Surgical Wounds; Trauma Wounds; Draining Wounds; Chronic Vascular Ulcer

Summary: the respond registry is an observational study to assess the impact of puraply™ am on the management of wounds in real world clinical settings; no experimental intervention is involved.

the purpose of this study is to assess the impact of puraply™ am on the management of wounds in real world clinical settings as it leads to an improvement in wound bed condition (i.e increase in healthy granulation tissue, reduction in bioburden, and reduction in amount of exudate). the respond registry is a prospective, non-interventional research initiative to collect information on patients who are eligible to receive puraply™ am, and no interventional procedures will be mandated by this protocol. enrolled and eligible patients will receive standard wound care clinical assessments and any additional care as determined by the treating wound care clinician. although multiple wounds may be treated simultaneously, one wound will be identified as the target wound, and characteristics regarding this wound will be consistently documented. the case series is being undertaken to better understand puraply™ am utilization and subsequent healing outcomes as well as to evaluate the effects of concomitant wound therapy on healing. patient's participation may involve follow-up for up to 24 weeks following application of puraply™ am.

Eligibility criteria:
inclusion criteria: * patient is at least 18 years of age. * patient, or their legally authorized representative (lar), has read, understood and signed and institutional review board (irb) approved informed consent form (icf). * patient has a wound appropriate for receiving puraply™ am, including: * partial or full-thickness wound * pressure ulcer * venous ulcer * diabetic ulcer * chronic vascular ulcer * tunneled/undermined wound * surgical wound (e.g., donor sites/graft, post-mohs' surgery, post-laser surgery, podiatric surgery wound, wound dehiscence) * trauma wound (abrasions, lacerations, second degree burns, and skin tears) * draining wound exclusion criteria: * patient has a known sensitivity to porcine materials. * patient has a third-degree burn. * patient has a known sensitivity to polyhexamethylenebiguanide hydrochloride (phmb). * patient's target wound was previously treated with puraply™ am.

Keywords: antimicrobial collagen bioburden biofilm phmb chronic wounds acute wounds
optimal hemostasis duration for percutaneous coronary intervention via snuffbox approach

Conditions: Bleeding; Artery Injury

Summary: transradial approach has been preferred for coronary angiography (cag) and percutaneous coronary intervention (pci) due to several advantages, including decreased associated vascular complication, patients' convenience, and early ambulation compared with transfemoral approach. with these advantages, current guidelines support that radial access is recommended for cag and pci in acute myocardial infarction (ami) patients with and without st-elevation if performed by an experienced radial operator. recently, kiemeneij introduced a distal radial artery approach, called the snuffbox approach, and several studies have been published. however, the feasibility of pci via snuffbox approach is still concerned due to the lack of data. moreover, optimal hemostasis duration for pci via snuffbox approach has not been investigated, even though shorter hemostasis duration would be expected compared with the conventional radial approach as diameter of snuffbox radial artery was significantly smaller than conventional radial artery. in addition, there are few data regarding the feasibility of pci via snuffbox approach. therefore, the aim of the study is to evaluate the optimal hemostasis duration for pci via snuffbox approach.


Eligibility criteria:
inclusion criteria: * patients ≥18 years old requiring pci * patients who are palpable distal radial arter * the decision to participate voluntarily in this study and the written consent of the patient exclusion criteria: * patients who are not palpable distal radial artery * female of childbearing potential, who possibly plans to become pregnant any time after enrollment into this study. * patients who are not appropriate for this study

Keywords: snuffbox approach distal radial approach hemostasis
sleep and circadian rhythms in mechanically ventilated patients

Conditions: Respiratory Failure; Critical Illness

Summary: this study examines the feasibility of assessing sleep and circadian rhythmicity in critically ill patients undergoing mechanical ventilation. secondarily, it will examine the feasibility of reducing subject exposure to environmental light and noise and of delivering routine care according to classical day/night routines.

over 1 million patients develop respiratory failure annually in the united states; yet, the sleep of patients undergoing mechanical ventilation has received little attention. this protocol enrolls acutely ill medical patients undergoing mechanical ventilation. the feasibility of assessing sleep and circadian rhythmicity through the use of continuous bedside polysomnography and the measurement of core body temperature and urinary hormonal levels at frequent intervals will be explored. as a secondary goal, the feasibility of delivering routine care according to classical day/night routines, and of employing various noise and light reduction strategies at night, will be explored in a subset of subjects.

Eligibility criteria:
inclusion criteria: * adults undergoing mechanical ventilation in the medical intensive care unit. exclusion criteria: * central nervous system disease (stroke, seizure, dementia, etc) * metabolic or hypoxic encephalopathy * confirmed or suspected drug overdose * currently receiving neuromuscular blockers * coma

Keywords: polysomnography circadian rhythmicity
effects of 24-week computerized cognitive training in patients with mci and ad

Conditions: Mild Cognitive Impairment; Alzheimer Disease

Summary: this study aims to testify multi-domain effects of computerized cognitive training in patients with mild cognitive impairment and mild alzheimer's disease through multi-dimensional evaluation.

this study aimed to elucidate the neural process enhancement and remodulation in gut microbes resulting from older adults with mci and mild ad in a randomized controlled trial of a 24-week computerized cognitive training (cct) program. after recruitment and baseline assessments, pairs of participants with mci and mild ad would be randomly allocated into the corresponding subgroup. participants in cct group will receive a computerized multidomain cognitive training program (www.66nao.com) and will be required to complete at least 30 minutes of training per day (3 cycle of 5 2-min tasks), 5 days a week for 24 weeks. adherence to the intervention will be supervised by an independent researcher. the number of training days and training hours per day will be recorded. patients in control group received treatment as usual (tau) for 24 weeks. the neuropsychological measures will be performed at baseline, follow-up at 4 weeks, 12 weeks, and 24 weeks; functional near-infrared spectroscopy (fnirs) data and fecal samples will collected at baseline and 24 weeks.

Eligibility criteria:
inclusion criteria: * between 55 and 90 years of age; * a clinical dementia rating (cdr) score of 0.5 or 1; * at least three months of stable doses if receiving antidementia medication or mood-stabilizing medication for mild ad participants; * primary school education and above; * accompanied by a consistent caregiver (at least 5 days/week); * informed consent. exclusion criteria: * factors that might preclude completion of assessments; * severe psychiatric illness and the use of antidepressants; * any condition that would preclude completion of training and follow-up tests; * other disorders that would affect cognition.

Keywords: computerized cognitive training functional near-infrared spectroscopy mild cognitive impairment alzheimer's disease brain-gut-microbiota axis gut microbiota
non-deceptive application of placebos in insomnia

Conditions: Insomnia

Summary: the purpose of this study is to evaluate whether non-deceptive application of a placebo has an impact on subjective or objective sleep parameters in patients with primary insomnia.


Eligibility criteria:
inclusion criteria: * age between 18 years to 69 years * fluent in german language * provide written informed consent * ability to understand the explanations and instructions given by the study physician and the investigator exclusion criteria: * evidence for sleep disorders caused by medical factors (e.g. sleep apnea, restless legs syndrome, narcolepsy, substance-induced insomnia) * allergies to ingredients of placebo * patients scoring below 8 or above 21 on the insomnia severity index * patients suffering from a mental disorder as verified by the scid * patients suffering from an acute physical illness * nicotine consumption \> 10 cigarettes/day * unwillingness to refrain from alcohol consumption throughout the study * change in concomitant medication regime during the last 2 weeks prior to visit 1 or after randomization * intake of psychotropic drugs during the last 3 months prior to visit 1 * currently pregnant (verified by urine pregnancy test) or lactating
neofent-i study; fentanyl treatment in newborn infants; a pharmacokinetic, pharmacodynamic and pharmacogenetic study

Conditions: Pain

Summary: the study will assess the efficacy of fentanyl using a pharmacokinetic/pharmacodynamic (pk/pd) model where the concentration of the drug is related to effect curve (pain score change in response to standardized procedural pain). further cortical, physiological and biochemical responses to fentanyl will be assessed, elucidating the feasibility before the main study project (neoopioid) start.


Eligibility criteria:
inclusion criteria: * clinical indication for analgesia before any of following procedures; 1. insertion of peripheral iv-catheter 2. insertion of arterial cannula 3. insertion of chest tube 4. other skin breaking procedure. * possibility to obtain blood samle after the procedure (indwelling line) * infants all gestational ages. * postnatal age 0-28 days * informed written parental concent exclusion criteria: * concurrent or previous opioid administration (72 h interval required) * abdominal surgery * major chromosomal anomaly * neonatal encephalopathy * use of muscle relaxant * hypothermia treatment after hypoxic-ischemic insult * clinical or biochemical evidence of hepatic failure * participation in other intervention trial

Keywords: analgesia neonates procedural pain pain assessment physiological response pharmacogenetics
nutrition, vision, and cognition in sport study: beef

Conditions: Cognitive Change; Nutrient Deficiency; Nutritional Anemia; Visual Spatial Processing; Diet, Healthy; Diet; Deficiency; Dietary Deficiency; Dietary B12 Deficiency; Dietary Zinc Deficiency; Dietary Vitamin B12 Deficiency Anemia; Dietary Deficiency of Selenium and Vitamin E

Summary: the purpose of this study is to determine whether a 30 day beef intervention can improve peak cognitive performance in young, normally menstruating adult women. the control group will consume a daily portion of macronutrient equivalent vegetable source of protein.

the purpose of the nutrition, vision, and cognition in health sport: beef (ionsport-beef) study is to conduct a randomized controlled trial to evaluate beef as a nutritional intervention to optimize visual cognitive training performance in generally healthy, normally menstruating women. female subjects of reproductive age (18-40) will be randomly placed in one of two dietary treatment groups: one serving of beef per day for 30 days or a non-meat protein replacement control. cognitive performance will be measured in 15 training sessions over 10 days using the sophisticated neurotracker™ core (nt) 3-dimensional (3d) software program. it is hypothesized that women consuming 1 serving of beef per day for 30 days will have the highest plasma levels of the beef rich nutrients and demonstrate the highest visual cognitive performance and improvement as compared to the no beef control.

Eligibility criteria:
inclusion criteria: 1. 18-40 year old female 2. eumenorrheic exclusion criteria: 1. neuroactive medications such as ritalin, adderall, antidepressants etc 2. dietary supplements 3. iron intake above 15mg/day 4. protein intake above 1.5 g/kg/day 5. more than 1 mild concussion lifetime or 1 mild concussion within the last 12 months 6. history of affective disorder 7. visual impairments uncorrected by glasses 8. amenorrhea or dysmenorrhea 9. currently being treated for anemia 10. \>3 servings of beef per week 11. \ 35 12. consume \>100mg caffeine/day (\>1 cup of coffee or soda) 13. \ 4 hours/week vigorous activity 14. depression score \>18 (beck depression inventory) 15. \<20 kcal/kg/day
feasibility study of pemetrexed in combination with cisplatin or carboplatin as adjuvant treatment of non-small cell lung cancer

Conditions: Non-Small Cell Lung Cancer

Summary: this study is a multicenter, open-label, two-arm, randomized, parallel phase 2 feasibility study of pemetrexed in combination with either cisplatin (arm a) or carboplatin (arm b) as adjuvant combination-chemotherapy in participants with completely resected, stage ib or iia/iib non-small cell lung cancer (nsclc). a two-stage design will be employed independently for both treatment arms, with the possibility of stopping each treatment early for lack of feasibility.


Eligibility criteria:
inclusion criteria: * histologically proven non-small cell lung cancer stage ib, iia or iib * must have complete tumor resection by pneumonectomy or lobectomy * must have been surgically proven to be n2 negative exclusion criteria: * serious concomitant systemic disorder * post-operative complications or other surgery related conditions * a prior malignancy other than nsclc unless that malignancy was diagnosed and treated at least 5 years ago
clam chemotherapy with pbsc support for relapsed patients after allogeneic stem cell transplantation

Conditions: Leukemia

Summary: for acute leukemia patients with early relapse after allogeneic stem cell transplantation, the overall outcome is poor. in this study, we evaluate the treatment outcome and safety of chemotherapy with cladribine, cytarabine and mitoxantrone followed by peripheral stem cell support from the original donor.

for acute leukemia patients experienced relapse 6 months or less after allogeneic stem cell transplantation, the overall outcome is poor. in this study, we design a treatment protocol aiming to achieve complete remission for this high-risk group of patients with chemotherapy consisting of cladribine (5mg/m2), cytarabine (1.5g/m2) and mitoxantrone （10mg/m2）for 5 days followed by infusion of mobilized peripheral stem cell from the original donor. for patients who failed to achieved remission,a second cycles will be given. for patients who achieved remission, the post-remission therapy is open depend on patient's intent: consolidation with one more cycle, second allo-hsct with different donor or continuous dli.

Eligibility criteria:
inclusion criteria: * patients with acute leukemia relapsed within 6 months after previous allo-hsct * no active gvhd * mobilized pbsc from the original donor available exclusion criteria: * ecog \>=3 * liver function/renal function damage (over 2 x upper normal range) * active infection including cmv and ebv
platelet rich plasma study in lower extremity bypass surgery

Conditions: Atherosclerosis

Summary: the use of platelet rich plasma will decrease wound infection postop.


Eligibility criteria:
inclusion criteria: * vascular surgical patients scheduled for elective lower extremity bypass surgery,aortoiliac revascularizations and endovascular aaa repair requiring a groin incision exclusion criteria:patients requiring emergent procedures, unable to give informed consent
oral dydrogesterone in the management of preterm labor

Conditions: Preterm Labor

Summary: this study evaluates the addition of oral dydrogesterone to standard treatment in the treatment of preterm labor. half of participants will receive oral dydrogesterone and standard treatment, while the other half will receive oral placebo and standard treatment.


Eligibility criteria:
inclusion criteria: * singleton pregnancy with gestational age 24-33 weeks 6 days * preterm labor * received treatment with tocolysis and corticosteroids exclusion criteria: * conditions that need immediate delivery such as fetal distress, chorioamnionitis * have medical complications such as heart disease, seizure * fetal anomalies * cervical dilatation more than 5 cm * allergy to dydrogesterone
efficacy testing of chenopodium formosanum extracts on skin beauty

Conditions: Skin Condition

Summary: to assess chenopodium formosanum extracts on skin condition improvement


Eligibility criteria:
inclusion criteria: * healthy adults aged above 20 years old exclusion criteria: * subject who is not willing to participate in this study. * patients with diseases of the skin, liver, kidney. * subjects who have known cosmetic, drug or food allergies, difficulty in digestive tract absorption or disorder. * female who is pregnant or nursing or planning to become pregnant during the course of the study. * received facial laser therapy, chemical peeling or uv overexposure (\> 3 hr/week) in the past 4 weeks. * constant drug use * students who are currently taking courses taught by the principal investigator of this trial.